Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Bed Bath & Beyond Inc. (NASDAQ: BBBY) Q1 earnings tumbled while revenues rose.
• Casella Waste Systems Inc. (NASDAQ: CWST) posted a narrower-than-expected Q4 loss.
• CKE Restaurants Inc. (NYSE: CKR) Q1 earnings increased but its revenue slipped.
• Darden Restaurants Inc. (NYSE: DRI) swung to a Q4 profit on strong sales at Olive Garden.
• Ericsson (NASDAQ: ERIC) said it might not see Q2 profit growth on lower demand and shipping delays.
• General Mills Inc. (NYSE: GIS) Q4 earnings declined but were in line with expectations.
• Gerber Scientific Inc. (NYSE: GRB) reported solid Q4 and full-year results that pleased investors.
• IHS Inc. (NYSE: IHS) beat Q2 expectations and posted record quarterly cash flow from operations.
• Jabil Circuit Inc. (NYSE: JBL) stronger-than-expected Q3 results led to an analyst's upgrade.
• KB Home (NYSE: KBH) widened its Q2 loss due to weak sales and falling prices.
• Kroger Co. (NYSE: KR) beat Q1 expectations as consumers sought discounts on food and gas.
• Monsanto Co. (NYSE: MON) beat Q3 earnings estimates but fell short of revenue estimates.
• Nike Inc. (NYSE: NKE) posted better-than-expected Q4 results boosted by international strength.
• Oracle Corp. (NASDAQ: ORCL) posted strong Q4 results that topped analysts' expectations (see transcript).

• Palm Inc. (NASDAQ: PALM) posted dismal results as revenue fell despite higher sales volume.
• Red Hat Inc. (NYSE: RHT) Q1 revenues soared as results beat Wall Street expectations.
• Research in Motion Ltd. (NASDAQ: RIMM) posted disappointing results and lackluster guidance (transcript).
• Rite-Aid Corp. (NYSE: RAD) swung ot a larger-than-expected Q1 loss on integration difficulties.
• Sonic Corp. (NASDAQ: SONC) earnings warning took shares to a new 52-week low.
• Symmetry Medical Inc. (NYSE: SMA) beat Q1 estimates on increased demand and acquisitions.
• United Parcel Serivce (NYSE: UPS) cut its earnings forecast due to rising fuel prices and less demand.
• Walgreen Co. (NYSE: WAG) posted sluggish Q3 results despite cost-cutting measures.

Also, do the results from Oracle, Research in Motion, and Red Hat point to a bottom for tech stocks? Will Google's (NASDAQ: GOOG) new CFO be more likely to provide the guidance that analysts crave?

Upcoming results to watch for include H&R Block (NYSE: HRB), Constellation Brands (NYSE: STZ), Apollo Group (NASDAQ: APOL), Family Dollar (NYSE: FDO), WD-40 (NASDAQ: WDFC), and Berkshire Hathaway (NYSE: BRK.A).

Visit AOL Money & Finance for more earnings coverage.

Permalink | Email this | Linking Blogs | Comments

Rite-Aid (NYSE: RAD), a competitor of CVS (NYSE: CVS) and Walgreen (NYSE: WAG), tanked Thursday. By the end of the trading session, the pharmacy's stock declined almost 23% on heavy volume. Yes, it was a horrible day in the market overall, but don't blame the market at large. Rite-Aid is simply a company to avoid, and its latest earnings data show why.

According to the AP, Rite-Aid booked a loss of $0.20 per share for its fiscal first quarter versus a profit of $0.04 per share in the year-ago period. There are some growing pains going on here, since Rite-Aid is attempting to integrate its purchase of Brooks Eckerd. That acquisition propelled the company to top-line revenue growth of 48%. Unfortunately, analysts were looking for the company to lose only $0.09 per share. The significant differential made investors feel justified in punishing the stock. Heck, I'll bless the sell-off myself.

It'll be a long time before Rite-Aid finally turns its ship around. The next fiscal year will bring more losses, and with strong competition out there from CVS and Walgreen, the road ahead for management won't be for the faint of heart. This is truly a speculator's stock. I took a look at a post I wrote on Rite-Aid back near the beginning of April. At that time, the stock was priced at about $2.89 per share. As of Thursday's close, the shares were trading for $1.35. The Rite-Aid story belongs in the horror genre, and its stock is best left to those professionals who don't mind losing money. Individual investors? This company isn't for you, in my opinion.

Disclosure: I don't own any company mentioned; positions can change at any time.

Read | Permalink | Email this | Linking Blogs | Comments

Walgreen (NYSE: WAG) reported sluggish Q3 numbers last week. Net sales increased a little under 10% to $15 billion. Net income increased a whopping two pennies to 58 cents per diluted share (the term "whopping" is used here sarcastically). According to this article, Walgreen met top-line expectations but missed the bottom-line call by a penny.

Gross margin remained relatively stable, but the net margin dropped to 3.8% in the quarter compared to 4.1% in the previous year's similar period. But same-store sales increased 3.4%, which is a decent number. Also, operational cash flow jumped over 19% to $2.5 billion. That's excellent; it's always good to see cash coming in. It helps mitigate the tepid earnings expansion. Walgreen did well with its cash-flow statement last time around as well. Walgreen management cited the economy as a factor in its earnings stats and highlighted the fact that it cut back on expenses, including advertising. Making sure costs don't get out of hand is important, but I'd be careful about eliminating too much of the advertising budget. Competing with CVS Caremark (NYSE: CVS), Rite-Aid (NYSE: RAD), and the pharmacy at Wal-Mart (NYSE: WMT) obligates brand-building and differentiation.

Walgreen's Q3 wasn't beyond awesome, but it was solid enough. The stock is only down slightly as I write this. As a long-term play on the need for drugstores, it's not a bad way to go.

Disclosure: I don't own any company mentioned; positions can change at any time.

Read | Read | Permalink | Email this | Linking Blogs | Comments

Though the quarter is winding down, there are still earnings reports to come, including Walgreen Co. (NYSE: WAG) and Kroger Co. (NYSE: KR). Both companies are expected to report profit growth this coming week.

Walgreen is expected by analysts surveyed by Thomson Financial to report third-quarter earnings of 59 cents per share, up 6.8% from the same period of last year, on revenue of $15.1 billion. The company has provided positive surprises in four of the past five quarters -- by two cents in the previous quarter.

Based in Deerfield, Ill., Walgreen is the largest drug store chain in the U.S. in terms of sales, and has more than 6,200 stores in the U.S. and Puerto Rico. In the past year, the company's revenues were $53.7 billion and its net income totaled $2.0 billion. Its long-term EPS growth forecast is 14.0%, which is less than the retail industry average, as well as less than that of rival CVS Caremark (NYSE: CVS). The consensus recommendation of analysts has recently shifted from hold to buy Walgreen.

The share price is up 4.0% since the beginning of the year, and up from 11.6% from a year ago. It trades at a P/E ratio of 20.68. Shares closed Friday at $41.35.

Kroger is expected to report first-quarter net income of 55 cents per share, up 10.9% from the year-ago period, on revenue of $22.3 billion. The company has provided positive surprises in the past five quarters -- by a penny in the previous quarter.

Cincinnati-based Kroger is the nation's largest grocery chain, though Wal-Mart (NYSE: WMT) sells more groceries. Kroger has more than 3,600 stores, including supermarkets, department stores, and convenience stores. In the past year, the company's revenues were $70.2 billion and its net income totaled $1.2 billion. The company's long-range EPS growth forecast is 10.6%, less than the industry average and slightly less than that of rival Safeway (NYSE: SWY). The consensus recommendation of analysts remains to buy Kroger.

The share price is up 4.7% in the past three months, but has fallen 11.9% from a year ago. It trades at a P/E ratio of 15.92. Shares closed Friday at $26.61.

Walgreen is scheduled to report earnings Monday morning, Kroger on Tuesday morning.

For more news that could influence the results, see BloggingStocks' Walgreen coverage and Kroger coverage.

Permalink | Email this | Linking Blogs | Comments

• Walgreens (NYSE: WAG) to report Q3 earnings; conference call at 8:30am.

• FOMC to hold two-day meeting.
• Jabil Circuits (NYSE: JBL) to report Q3 earnings; conference call at 4:30pm.
• 3Com (NASDAQ: COMS) to report Q4 earnings; conference call at 5:00pm.

• Second day of two-day FOMC meeting; announcement at 2:15pm.
• Thornburg Mortgage (NYSE: TMA) to discuss valuation and accounting for recent financing transaction at 10:00am.
• Nike (NYSE: NKE) to report Q4 earnings; conference call at 5:00pm.
  
• Oracle (NASDAQ: ORCL) to report Q4 earnings; conference call at 5:00pm.
• Research in Motion (NASDAQ: RIMM) to report Q1 earnings; conference call at 5:00pm.

• PDUFA date for Eli Lilly & Co's (NYSE: LLY) and Daiichi Sankyo's new drug application for Prasugrel.
• Palm Inc (NASDAQ: PALM) to report Q4 earnings; conference call at 4:30pm.
• Micron Technology (NYSE: MU) to report Q3 earnings; conference call at 4:30pm.

• PDUFA date for Indevus Pharmaceuticals' (NASDAQ: IDEV) New Drug Application for Nebido for treatment of male hypogonadism.
• PDUFA date for Johnson & Johnson's (NYSE: JNJ) and Eisai Co's (OTC: ESALY) Aciphex.
  

Permalink | Email this | Linking Blogs | Comments

Permalink | Email this | Linking Blogs | Comments

MOST NOTEWORTHY:

• Thomas Weisel started shares of Walgreen (NYSE: WAG) with an Overweight rating and $43 target. The firm is positive on WAG's steady cash flow and solid growth profile.
  
• Merriman believes Crown Castle (NYSE: CCI) is a core wireless holding given its high-margin, predictable recurring revenue model. They believe shares can trade to the $49-$51 range assuming management continues to execute on its free cash flow growth target. Shares were assumed with a Buy rating.
  
• KeyBanc initiated Brunswick (NYSE: BC) with a Hold rating and expects the recreational marine market to be challenging given weakening consumer spending trends.

• Citigroup initiated Gerdau AmeriSteel (NYSE: GNA) with a Buy rating and $21 target.
  
• Piper assumed Teradyne (NYSE: TER) with a Neutral rating and $14 target.
  
• International Speedway (NASDAQ: ISCA) was initiated at Stephens with an Overweight rating and $50 target.

Permalink | Email this | Linking Blogs | Comments

EMC (NYSE:EMC) Cut To Market Perform from Outperform at Bernstein, according to 24/7 Wall St. The financial website also reports that Netflix (NASDAQ:NFLX) Raised to Overweight at Lehman.

Thomas Weisel initiates Walgreen (NYSE:WAG) as "overweight" according to Briefing.com. Friedman Billings has taken Symantec (NASDAQ:SYMC) off its "best picks" list.

Douglas A.McIntyre is an editor at 247wallst.com.

Read | Permalink | Email this | Linking Blogs | Comments

Coinstar (NASDAQ: CSTR) offers North American and U.K. retailers a range of storefront service and entertainment devices. These include coin counters, kiddie rides, bulk vending machines, skill-crane games and point-of-sale terminals. The firm also provides self-service DVD movie rental/purchase kiosks and provides money transfer services, prepaid wireless products, stored value cards, payroll cards and prepaid debit cards. Coinstar products and services are distributed through more than 53,000 retail stores. Corporate clients include Wal-Mart (NYSE: WMT), Kroger (NYSE: KR) and Walgreen (NYSE: WAG).

The company surprised the Street last week, when it reported Q1 EPS of 18 cents and revenues of $190.5 million. Analysts had been expecting four cents and $182.7 million. Management also guided Q2 EPS to 8-15 cents (12 cent consensus), Q2 revenues to $200-$210 million ($202.19M consensus), FY08 EPS to 60-75 cents (57 cent consensus) and FY08 revenues to $850-$900 million ($829.83M consensus). DA Davidson subsequently upgraded the stock to "buy".

The CSTR share price popped on the news and then settled into a bullish "flag" consolidation pattern. Prices frequently exit flags moving in the same direction they were traveling on entry. In this case, that would be to the upside.

Altogether, brokers recommend the issue with five "strong buys", three "buys", four "holds" and one "underperform". Analysts expect an 18% average annual growth rate, through the next five years. The CSTR Price to Sales ratio (1.85), Price to Book ratio (3.32), Sales Growth rate (43.99%) and EPS Growth rate (100.00%) compare favorably with industry, sector and S&P 500 averages. Institutional investors hold about 95% of the outstanding shares. Over the past 52 weeks, the stock has traded between $24.69 and $38.00. A stop-loss of $31.45 looks good here.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com. He does not hold positions in any of the stocks mentioned above.

Permalink | Email this | Linking Blogs | Comments

"Shares of Walgreen (NYSE: WAG) have come under pressure in recent months, reflecting a slowdown in sales because of a weakening economy and intensifying competition," notes Richard Moroney.

The editor of Dow Theory Forecasts adds, "However, Walgreen's long-term prospects remain appealing, and the stock is attractively valued. Walgreen is a Long-Term Buy." Here is his review.

"Big, strong, and healthy, Walgreen is the largest U.S. drugstore chain as measured by revenue and the second-largest based on store count.

"The company operates more than 6,200 stores in 48 states and Puerto Rico and plans to boost the count to 7,000 by fiscal 2010 ending August. Walgreen sees long-term potential for about 13,000 U.S. stores. Prescriptions generate about 65% of total sales, with the rest coming from general merchandise.

"In fiscal 2007, both pharmacy and general merchandise sales growth outpaced the industry average, and Walgreen increased market share in nearly all of its core categories.

"2007 represented the company's 33rd consecutive year of sales growth. Walgreen has expanded beyond pharmacy services with in-store health clinics and a managed-care division.

"Walgreen has not traditionally been an aggressive acquirer, relying mostly on such strategies as building
new stores, entering new markets, and improving customer service. The company has also invested heavily in technology enhancements that improve pharmacy effi ciency and reduce costs.

"But in recent months, Walgreen has made several deals that will broaden its health-care offerings. In September, Walgreen paid $850 million for OptionCare, which specializes in infusion drugs such as
cancer treatments.

"The deal was the largest in Walgreen's history and made the company the nation's largest independent specialty pharmacy. The specialty-pharmacy market is growing much faster than the overall pharmacy market.

"In March, Walgreen agreed to acquire I-trax and Whole Health Management, which operate health centers at corporate offices, paying $260 million for I-trax and an undisclosed amount for Whole Health. After those deals close, Walgreen will operate more than 500 worksite and retail health centers in 40 states, including its in-store clinics.

"The weakening economy and increasing competition have slowed growth of both pharmacy and general merchandise sales in recent months. Walgreen has also cut back on advertising spending to reduce expenses, and some investors worry about the affect on market share.

"However, the company continues to offer customers more convenience and new services. Expanded store operating hours, a growing number of free-standing stores with drive-through pharmacies, and in-store digital photo-fi nishing labs should boost customer traffic.

"The stock looks cheap relative to its solid growth outlook. At 15 times estimated year-ahead earnings of $2.36 per share, Walgreen trades well below its five-year average forward P/E of 23. Consensus estimates project per-share-profit growth of 9% in fiscal 2008 ending August and 12% in fiscal 2009, targets the company should be able to beat."

Each day, Steven Halpern's TheStockAdvisors.com offers the latest market commentary and favorite investment ideas from the nation's leading financial newsletter advisors.

Permalink | Email this | Linking Blogs | Comments

"Socially Responsible Investing (SRI) is no longer relegated to a tiny corner of the investment landscape; indeed, according to the Social Investment Forum, SRI now accounts for $2.7 trillion, up more than 18% since 2005," says Chuck Carlson.

Here, the editor of The DRIP Investor offers five stock that both rank high for their social responsibility and also stand out based on more traditional earnings and valuation analysis.

"The Social Investment Forum estimates that more than one in every 10 dollars under professional management in the U.S. is involved in SRI investing. What is driving the growth in SRI?

"One factor is the increasing numbers of women and younger investors among the investor populace have fueled demand for SRI investments.

"In addition, we see an increased focus on environment, social, and corporate governance issues. Further, widely publicized stories concerning global warming as well as various corporate governance issues, have caused many investors to reconsider how they deploy their investment capital.

"The most prominent of all the SRI market indexes is the KLD Domini 400 Social Index. The index employs a variety of environmental and social screens when selecting components. In a nutshell, the index selects companies that have positive environmental, social, and governance performance.

"To be sure, I've always been a bit tentative about the concept of SRI investing. It seemed to me that to pick stocks solely on SRI criteria left out an important part of the equation - investment merit.

"Because traditional SRI investing often excludes important investment factors such as earnings and valuation. Still, plenty of stocks exist within the SRI framework that adhere to SRI principles yet offer outstanding return potential for investors."

Chuck Carlson adds that five stocks that rank highly according to SRI are also members of his Editor's Portfolio, which is determined by investment merit. They are Paychex (NASDAQ: PAYX), PepsiCo (NYSE: PEP), Procter & Gamble (NYSE: PG), Regions Financial (NYSE: RF), and Walgreen (NYSE: WAG).

In addition, he adds, "Among other favorites, I especially like Microsoft (NASDAQ: MSFT) as a stock offering a compelling buying opportunity. I think Wall Street's concern that Microsoft will overpay for Yahoo is overshadowing the company's solid growth prospects. I expect the stock to move sharply higher once there is greater clarity on the Yahoo deal."

Each day, Steven Halpern's TheStockAdvisors.com offers the latest market commentary and favorite investment ideas from the nation's leading financial newsletter advisors.

Permalink | Email this | Linking Blogs | Comments

Financial Stocks to Love
The subprime mortgage meltdown and resulting credit crisis have slammed financial stocks recently. But there are still some diamonds in the rough. They include Berkshire Hathaway, RBS, AFLAC, Raymond James and BOK.
Financial stocks we love - CNNMoney.com

Big Mac's Local Flavor
Once vilified for pushing America on the world, McDonald's lets countries invent their own buns, bags, and business practices. Now some ideas are making their way back home.
Big Mac's local flavor - FORTUNE

America's Best Drugstores
Consumer Reports readers rate service, speed, and advice (but too few ask for it). The top rated stores include Medicine Shoppe for independents, Publix for supermarkets and Kmart for mass merchants. The worst rated include RiteAid for independents, GiantEagle for supermarkets and Wal-Mart for mass merchants. The top-rated online drugstores were Walgreens for store websites and CaremarkRx for pharmacy benefit managers.
ConsumerReports.org - Drugstores: Ratings, finding the best store
ConsumerReports.org - Drugstores, which store is best for you?
Top Rated Drugstores Best Online Drugstores

Where to Find the Biggest Savings at Drugstores
Consumer Reports study of prices for four drugs at 13 stores and Web sites turned up big differences in prices. The moral if you pay out of pocket: Call different stores. Costco offered the biggest savings overall. Some Web sites, including AARP.com and Drugstore.com, were also relatively inexpensive, and shipping costs are low or nonexistent. Rite-Aid and Walgreens were the most expensive.
ConsumerReports.org - Drugstores, where to find the biggest savings

Permalink | Email this | Linking Blogs | Comments

CVS Caremark

Looking through the reported growth rates, you can see that we're talking best-of-breed here. Revenues were up over 60%, and adjusted earnings per share increased over 18%, coming in at $0.55. The Caremark merger has obviously proven to be a good move. Same-store sales rose 3.9%, benefited in part by the early appearance of Easter in March.

According to earnings.com, CVS Caremark basically matched earnings expectations. That's okay, though, I don't think you can hold it against this big brand name. As of this writing, CVS is near a 52-week high. Buying at the 52-week high is always a dicey thing, but if you plan on holding for years, it wouldn't be that much of a concern. Shorter-term traders would need to wait for a pullback. But I like the first quarter results for CVS, and I think the stock is poised to do well over time. And like I said at the beginning, this really may be a stock for the core portion of an individual's investment program -- a true buy-and-hold idea.

Disclosure: I don't own shares in any company mentioned here; positions can change at any time.

Permalink | Email this | Linking Blogs | Comments

This post is part of our Battle of the Brands feature. Let us know which brand you prefer, and check out other Battle of the Brands posts.

CVS Caremark Corp (NYSE: CVS) -- with 6,200 stores and a pharmacy benefits management division -- beats Walgreen Co. (NYSE: WAG) -- with 5,997 stores -- hands down in the battle of the brands. It's bigger, its earnings are growing faster, it has a higher P/E and its stock has grown faster over the last year and five years. Walgreen wins on one measure: it has a fatter profit margin.

Here's how the two score on these measures:

• Revenues. $76 billion (CVS) beats $54 billion (Walgreens)
• Earnings growth. 12% (CVS) beats 6% (Walgreens)
• Profit margins. 3.8% (Walgreens) beats 3.45% (CVS)
• P/E. 21.3 (CVS) beats 17 (Walgreens)
• One year stock performance.+16% (CVS) beats -22% (Walgreens)
• Five year stock performance. +250% (CVS) beats +16% (Walgreens)

Peter Cohan is President of Peter S. Cohan & Associates. He also teaches management at Babson College and edits The Cohan Letter. He has no financial interest in the securities mentioned.

Vote in our poll for CVS or Walgreens as your preferred brand, and let us know in the comments why you love it.

Permalink | Email this | Linking Blogs | Comments

Rite Aid (NYSE: RAD), I should disclose, is one of my least favorite companies and stocks. Nevertheless, I don't mind checking in on it from time to time when there is news about it. Yesterday, the pharmacy released sales data for the month of March (the data excludes the Brooks Eckerd acquisition). Did they change my outlook on Rite Aid at all?

No, although I should say that this wouldn't be necessarily expected; a month of same-store sales data isn't the killer app of an overall investment thesis for a retail idea. Still, shareholders follow comps religiously, and I have to say that Rite Aid's number was nothing to write home about. A 2.6% gain in sales at stores open more than a year is weak. Walgreen (NYSE: WAG) said earlier in the week that its comparable-store revenues grew by a much better 4.4%. Walgreen was able to take advantage of the Easter shopping excitement in a much better fashion than Rite Aid. It all comes down to brand and execution; Walgreen, as well as CVS Caremark (NYSE: CVS), are more valuable in terms of both those attributes.

I may not have been bowled over by Walgreen's recent earnings release, but I can tell you that Rite Aid's share price is downright frightening and telling -- it's telling people to stay away, or at least understand that it may be essentially like buying a lottery ticket (it closed at $2.89 yesterday). Rite Aid's same-store sales were weak, and so is its investment potential.

Disclosure: I don't own shares in any of the companies mentioned here; positions can change at any time.

Permalink | Email this | Linking Blogs | Comments

MAJOR PAPERS:

• Luqman Arnold, the former UBS AG (NYSE: UBS) president forced out in 2001, wants the firm to split its investment bank from the private client bank, and look at selling the investment bank and asset management business, according to the Wall Street Journal's "Heard on the Street".
• Microsoft Corporation's (NASDAQ: MSFT) bid to acquire Yahoo! Inc (NASDAQ: YHOO) has not gained any steam even though executives of the two companies met this week, the Wall Street Journal reported.
• The Financial Times reported that the landmark merger that created Citigroup Incorporated (NYSE: C) was a "mistake" that failed to benefit the financial services giant's investors, customers and employees, said John Reed, who masterminded the $166B deal with Sandy Weill in 1998. Reed, the former head of Citicorp, has advised Citigroup CEO Vikram Pandit at least to consider spin-offs, sources said.

• Walgreen Co (NYSE: WAG) is branching out by acquiring two companies that provide health-care services, BusinessWeek reported, following in its competitor CVS Caremark Corporation's (NYSE: CVS) shoes. Some investors are wary of Walgreen's move, but Mark Wiltamuth of Morgan Stanley sees it as a new growth avenue and as a push into services complementary to drugstores.

Permalink | Email this | Linking Blogs | Comments

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• AAR Corp. (NYSE: AIR) posted record third-quarter earnings and revenue.
• Adobe Systems Inc. (NASDAQ: ADBE) posted better-than-estimated first-quarter results and raised its outlook.
• CKE Restaurants Inc. (NYSE: CKR) posted third-quarter results that missed estimates.
• ConAgra Foods Inc. (NYSE: CAG) third-quarter profit surged as strong sales offset commodity prices.
• Darden Restaurants Inc. (NYSE: DRI) beat third-quarter expectations and offered guidance.
• FactSet Research Systems Inc. (NYSE: FDS) second-quarter results beat estimates and it raised its outlook.
• Fortress Investment Group (NYSE: FIG) remained upbeat despite a fourth-quarter loss.
• Guess Inc. (NYSE: GES) record fourth-quarter results beat Wall Street expectations.
• Inter Parfums Inc. (NASDAQ: IPAR) posted better-than-estimated fourth-quarter results and raised its outlook.
• Jabil Circuit Inc. (NYSE: JBL) beat second-quarter expectations but lowered its guidance.
• JC Penney Co. Inc. (NYSE: JCP) lowered its first-quarter outlook on weaker-than-expected sales.
• KB Home (NYSE: KBH) swung to a larger-than-expected first-quarter loss on write-downs.
• Lennar Corp. (NYSE: LEN) posted a smaller-than-expected first-quarter loss.
• Monsanto Co. (NYSE: MON) raised its second-quarter and full-year guidance.
• Oracle Corp. (NASDAQ: ORCL) merely met earnings expectations, sending shares lower.
• Tiffany & Co. (NYSE: TIF) posted better-than-estimated fourth-quarter results and raised its outlook.
• Usana Health Sciences Inc. (NASDAQ: USNA) posted lower-than-expected first-quarter results.
• Walgreen Co. (NYSE: WAG) posted solid second-quarter results, including same-store sales growth.

Also, auction-rate securities issues may hurt some tech company results. Analysts keep cutting earings estimates for the big banks, but some are eyeing Yum! Brands (NYSE: YUM) earnings prospects as it expands in China, as well as Archer Daniels Midland (NYSE: ADM) on soaring demand for commodities.

Upcoming results to watch for include Best Buy (NYSE: BBY), Monsanto (NYSE: MON), and Research in Motion (NASDAQ: RIMM).

Visit AOL Money & Finance for more earnings coverage.

Permalink | Email this | Linking Blogs | Comments

Walgreen Company (NYSE: WAG) reported earnings for the second quarter on Monday. Net sales grew by a very decent 10%. Diluted earnings per share for the quarter were $0.69 versus $0.65 in the year-ago period; this represents a bottom-line gain of 6%.

Considering some of the other action on Wall Street on Monday -- the increased offer for Bear Stearns, the approval of the Sirius/XM merger -- Walgreen's earnings report was simply an okay event, even though the stock closed up around 5% on the news. Same-store sales may have increased 4.7%, but the retailer sold a lot of items with lower margins this time around, thus reducing its gross-margin metric by 14 basis points (the release did cite a big shift to pharmacy sales in the quarter as having negatively impacted margins). So Walgreen needs to work on its non-pharmacy revenues. One cool thing from the report is the jump in net cash from operations -- that number increased by 10%.

Walgreen, which competes with CVS Caremark Corporation (NYSE: CVS) and Rite Aid Corporation (NYSE: RAD), isn't a bad way to play the long-term drug-retailing business. To be sure, baby boomers -- as well as everyone else -- will always need to visit drugstores on a go-forward basis. It's the company that can capture a significant amount of non-pharmacy sales that will prosper the most. Walgreen and CVS are excellent brand names in this sector -- I'm not so keen on Rite Aid, though (take a look at the stock price and see if you think the company might be cheap-for-a-reason, as they say).

Disclosure: I don't own any shares in any of the companies mentioned here; positions can change at any time.

Permalink | Email this | Linking Blogs | Comments

Permalink | Email this | Linking Blogs | Comments

Permalink | Email this | Linking Blogs | Comments